sing GGT/platelet ratio for assessment of liver function and comparing it with Fibroscan study
Not Applicable
- Conditions
- Health Condition 1: K70-K77- Diseases of liverHealth Condition 2: K00-K95- Diseases of the digestive system
- Registration Number
- CTRI/2023/11/059369
- Lead Sponsor
- Dr Eshan Taneja
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients at risk of parenchymal liver disease undergoing Fibroscan as part of standard of care With main focus on known etiology of NAFLD ,Hepatitis B ,Hepatitis C who are able to give written informed consent
Exclusion Criteria
DERRANGED PLATELET COUNT ( <1,00,000 or >3,50,000)
Known case of cholestasis
Alcoholic Liver Disease ( 40-80 g/day of alcohol consumption in me and >20g/day in women)
Patient with Cardiac Pacemaker
Technical difficulty (Ascites, Pregnancy)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To calculate the GGT/Platelet ratio in patients with chronic hepatitis B,C <br/ ><br>and non-alcoholic fatty liver disease <br/ ><br>Timepoint: At presentation (baseline) <br/ ><br>
- Secondary Outcome Measures
Name Time Method To compare the GGT/Platelet ratio with grade of fibrosis found on Fibroscan & with AST/ALT RatioTimepoint: At presentation (baseline) <br/ ><br>